. 2006 Aug;50(8):2772–2781. doi: 10.1128/AAC.00127-06

TABLE 4.

Cross-resistance of VRX-329747-selected viruses to current HIV-1 drugs and RCs of viruses carrying VRX-329747-selected mutations in the absence of compound^a

Compound	Mean EC₅₀ ± SD (nM) for wt	Mean change (fold) in EC₅₀ ± SD^b
Compound	Mean EC₅₀ ± SD (nM) for wt	M184V	V118I-M184V	M41L-V118I- M184V	A62T-V118I-M184V	M41L-S68N-G112S-M184V	M41L-A62V- S68N-G112S-M184V	M41L-A62V-S68N-G112S-V118I-M184V	G112S-M184V
VRX-329747	176.9 ± 1.6	3.5 ± 1.0*	3.3 ± 0.6*	6.5 ± 1.6*	6.3 ± 1.0*	10.3 ± 0.4*	Max*	34.7 ± 18.6*	ND
VRX-413638	45.1 ± 0.5	3.9 ± 0.3*	4.2 ± 0.8*	9.8 ± 0.6*	9.5 ± 4.2*	36.5 ± 3.0*	Max*	Max*	ND
Efavirenz	0.7 ± 0.1	0.7 ± 0.02	0.6 ± 0.01	0.6 ± 0.01	0.5 ± 0.05	0.2 ± 0.02	0.3 ± 0.02	0.2 ± 0.002	ND
AZT	60.8 ± 1.2	0.5 ± 0.05	0.4 ± 0.07	0.4 ± 0.04	0.5 ± 0.02	0.1 ± 0.01	0.1 ± 0.02	0.1 ± 0.03	ND
ddI	2,636.5 ± 841	2.4 ± 0.4	2.2 ± 0.9	1.7 ± 0.2	1.9 ± 0.9	1.4 ± 0.5	0.3 ± 0.2	0.7 ± 0.2	ND
d4T	1,221.0 ± 255	1.3 ± 0.2	1.3 ± 0.3	1.1 ± 0.3	1.1 ± 0.1	0.6 ± 0.2	0.4 ± 0.02	0.4 ± 0.1	ND
Abacavir	1,647.5 ± 126	4.7 ± 1.4*	4.9 ± 1.0*	2.6 ± 0.3*	3.0 ± 0.7*	1.4 ± 0.1	0.6 ± 0.2	0.7 ± 0.2	ND
Tenofovir	555.5 ± 122	1.0 ± 0.3	1.0 ± 0.04	1.0 ± 0.3	1.1 ± 0.1	0.5 ± 0.1	0.5 ± 0.3	0.4 ± 0.1	ND
FTC	76.7 ± 7.9	Max*	Max*	Max*	Max*	Max*	Max*	Max*	ND
% wt RC^c	100	85.2 ± 7.9	119.9 ± 11.1	81.8 ± 4.7	121.6 ± 12.6	143.8 ± 10.2	15.9 ± 1.1	105.9 ± 12.1	0.2 ± 0.04

Molecular clones were built in the reporter vector pNL4-3.Luc.R−E, and EC₅₀ values were determined using HeLa-JC-53 cells.

Mean EC₅₀ values ± SD were from two tests. Max, could not be determined because the EC₅₀ was >10 μM; ND, not determined because of the poor replication capacity of the virus. *, EC₅₀ was statistically significantly higher than that against wild-type virus (P < 0.05).

Virus replication capacity was determined in the absence of inhibitor.